(IN BRIEF) Novartis will present new data from 27 abstracts at the 2025 American College of Rheumatology (ACR) Convergence, featuring late-breaking Phase III results from the NEPTUNUS-1 and NEPTUNUS-2 trials of ianalumab in Sjögren’s disease, which could become the first … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged ACR 2025, allergy, Angelika Jahreis, autoimmune diseases, Basel, biologics, biomarker research, CAR-T therapy, Cosentyx, Dermatology, EXPLORE44, Fortitude, HARBOR trial, ianalumab, immunology, NEPTUNUS trials, NEPTUNUS-1, NEPTUNUS-2, Novartis, Novartis Highlights Strong Immunology Pipeline with Positive Phase III Sjögren’s Results and CAR-T Data in Lupus at ACR 2025, Phase III data, psoriatic arthritis, rapcabtagene autoleucel, rheumatology, secukinumab, Sjögren’s disease, small molecules, systemic lupus erythematosus, YTB323
(IN BRIEF) Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm’s expertise in customized nucleic acids with Evonik’s advanced lipid and lipid nanoparticle (LNP) drug product development solutions. This collaboration aims … Read the full press release
Posted in Business, Chemicals, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged active ingredients, capping library screening, clinical trials, drug delivery, drug development, drug product development, enzymatic biotransformation, Evonik, Evonik capabilities, Fill & Finish, gene delivery, gene therapies, GMP manufacturing, Health Care Business, Kris S. Choi, life sciences sector, lipid nanoparticle, lipids, liposomes, LNP, mRNA development, mRNA-LNPs, North America manufacturing, nucleic acid medicines, nucleic acid therapeutics, nucleic acid therapies, Nutrition & Care division, oligonucleotides, partnership, pharmaceutical companies, RNA market, RNA therapeutics, siRNAs, small molecules, SmartCap® technology, South Korea, ST Pharm, strategic partnership, Yann d'Hervé
(PRESS RELEASE) VALBY, 4-Aug-2021 — /EuropaWire/ — Lundbeck (CPH: LUN), a Danish international pharmaceutical company, has announced it will partner with Rgenta Therapeutics, Cambridge, MA-based developer of oral, small-molecule RNA-targeting medicines with an initial focus on oncology, to discover small … Read the full press release
Posted in Denmark, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged disease-causing genes, Klaus Bæk Simonsen, Lundbeck, neuroscience, Rgenta Therapeutics, RNA pathways, RNA regulation, Simon Xi, small molecule RNA modulators, small molecules, Tarek Samad, treatments for brain diseases
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?